Analyst Ram Selvaraju noted that the Xiaflex approval was a
significantcatalyst for Auxilium and sees launch within the coming weeks. He comments,
In our view, this indication is tailor-made for Auxilium's urology-focused specialty sales force. Furthermore, as has been pointed out previously, the significantly higher number of vials of Xiaflex required to treat each Peyronie's disease patient is likely to translate into much greater revenue per patient in this indication vs. Dupuytren's contracture. In our view, Xiaflex could become a blockbuster (>$1bn in annual sales) based on usage in Peyronie's disease.
Another upcoming catalyst for Auxilium will be frozen shoulder and cellulit proof-of-concept data, which is expected to be released within the next 12 to 15 months. Selvaraju sees cellulite as the most potential value driver of the two. Data from that phase 2a trial is expected in Q115.
For an analyst ratings summary and ratings history on Auxilium Pharmaceuticals click here. For more ratings news on Auxilium Pharmaceuticals click here.
Shares of Auxilium Pharmaceuticals closed at $20.65 yesterday, with a 52 week range of $13.87 to $22.14.